Codiak BioSciences, Inc.·4

Feb 21, 4:32 PM ET

Bain Linda 4

4 · Codiak BioSciences, Inc. · Filed Feb 21, 2023

Insider Transaction Report

Form 4
Period: 2022-08-16
Bain Linda
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-02-16+7,61315,982 total
  • Sale

    Common Stock

    2023-02-17$0.59/sh2,570$1,52213,412 total
  • Exercise/Conversion

    Restricted Stock Units

    2022-08-167,61322,837 total
    Common Stock (7,613 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2023-02-167,61315,224 total
    Common Stock (7,613 underlying)
  • Exercise/Conversion

    Common Stock

    2022-08-16+7,61310,733 total
  • Sale

    Common Stock

    2022-08-17$2.21/sh2,364$5,2318,369 total
Footnotes (4)
  • [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  • [F2]The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
  • [F3]Each RSU represents a contingent right to receive one share of common stock.
  • [F4]On February 16, 2022, the reporting person was granted 30,450 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION